Drug Trial Radar · NCT03554109
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 2018
Primary completion
Jun 2020
Study completion Feb 9, 2022
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel (control arm).
Conditions
- Triple Negative Breast Cancer (TNBC)
Interventions
LeucovorinDrug
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
5-FluorouracilDrug
5-fluoro-2,4 (1H,3H)-pyrimidinedione
Aldoxorubicin HClDrug
albumin-binding prodrug of doxorubicin HCl
nab-PaclitaxelDrug
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
ETBX-051Biological
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061Biological
Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
GI-4000Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
GI-6207Biological
CEA yeast vaccine
GI-6301Biological
Brachyury yeast vaccine
AvelumabDrug
Avelumab
ALT-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex
haNKBiological
NK-92 \[CD16.158V, ER IL-2\]
CyclophosphamideDrug
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Doxorubicin HCLDrug
Doxorubicin HCL
paclitaxelDrug
paclitaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response RateTime frame: 8 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.